References
1. WHO. COVID-19 Epidemiological Update Edition 159. 09/09 2023;
2. Ge J, Pletcher MJ, Lai JC. Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study. Gastroenterology. Nov 2021;161(5):1487-1501.e5. doi:10.1053/j.gastro.2021.07.010
3. Singh S, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study. Gastroenterology. Aug 2020;159(2):768-771.e3. doi:10.1053/j.gastro.2020.04.064
4. Fix OK, Blumberg EA, Chang KM, et al. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology (Baltimore, Md). Aug 2021;74(2):1049-1064. doi:10.1002/hep.31751
5. Marjot T, Eberhardt CS, Boettler T, et al. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. Journal of hepatology. Oct 2022;77(4):1161-1197. doi:10.1016/j.jhep.2022.07.008
6. Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md). Aug 2020;72(2):671-722. doi:10.1002/hep.31065
7. Fishman JA. Opportunistic infections--coming to the limits of immunosuppression? Cold Spring Harbor perspectives in medicine. Oct 1 2013;3(10):a015669. doi:10.1101/cshperspect.a015669
8. Zecher BF, Buescher G, Willemse J, et al. Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey. United European gastroenterology journal. Sep 2021;9(7):797-808. doi:10.1002/ueg2.12100
9. Efe C, Lammert C, Taşçılar K, et al. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver international : official journal of the International Association for the Study of the Liver. Mar 2022;42(3):607-614. doi:10.1111/liv.15121
10. Efe C, Taşçılar K, Gerussi A, et al. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. Journal of autoimmunity. Oct 2022;132:102906. doi:10.1016/j.jaut.2022.102906
11. Duengelhoef P, Hartl J, Rüther D, et al. SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. United European gastroenterology journal. Apr 2022;10(3):319-329. doi:10.1002/ueg2.12218
12. Hartl J, Rüther DF, Duengelhoef PM, et al. Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis. Liver international : official journal of the International Association for the Study of the Liver. Feb 2023;43(2):393-400. doi:10.1111/liv.15368
13. Jorgensen K, Chopra A, Sexton J, et al. Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study. Journal of hepatology. 2022;77:S309.
14. Schneider L, Schubert L, Winkler F, Munda P, Winkler S, Tobudic S. SARS-CoV-2 Vaccine Response in Patients With Autoimmune Hepatitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Sep 2022;20(9):2145-2147.e2. doi:10.1016/j.cgh.2022.04.006
15. Zhou H, Ye Q. Clinical Features of COVID-19 Vaccine-Associated Autoimmune Hepatitis: A Systematic Review. Diseases (Basel, Switzerland). May 30 2023;11(2)doi:10.3390/diseases11020080
16. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical research ed). Jul 21 2016;354:i4086. doi:10.1136/bmj.i4086
17. Moons KG, de Groot JA, Bouwmeester W, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS medicine. Oct 2014;11(10):e1001744. doi:10.1371/journal.pmed.1001744
18. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000;
19. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. 2008;
20. Barnes E, Goodyear CS, Willicombe M, et al. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature medicine. Jul 2023;29(7):1760-1774. doi:10.1038/s41591-023-02414-4
21. Zecca E, Rizzi M, Tonello S, et al. Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort. Viruses. Aug 12 2022;14(8)doi:10.3390/v14081766
22. Chauhan M, Nzeako I, Li F, Thuluvath PJ. Antibody response after a booster dose of SARS-CoV-2 vaccine in liver transplant recipients and those with chronic liver diseases. Annals of Hepatology. 2022;27(4):100702.
23. Moriya K, Nakakita T, Nakayama N, et al. SARS-CoV-2 Vaccination Response in Japanese Patients with Autoimmune Hepatitis: Results of Propensity Score-Matched Case–Control Study. Journal of Clinical Medicine. 2023;12(16):5411.
24. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. Journal of hepatology. Dec 2014;61(6):1385-96. doi:10.1016/j.jhep.2014.08.010
25. Simon D, Tascilar K, Krönke G, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nature communications. Jul 24 2020;11(1):3774. doi:10.1038/s41467-020-17703-6
26. Moderbacher CR, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996-1012. e19.
27. Tan AT, Linster M, Tan CW, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell reports. Feb 9 2021;34(6):108728. doi:10.1016/j.celrep.2021.108728
28. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (New York, NY). Feb 5 2021;371(6529)doi:10.1126/science.abf4063
29. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature reviews Immunology. Aug 2021;21(8):475-484. doi:10.1038/s41577-021-00578-z
30. Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nature medicine. Jul 2021;27(7):1147-1148. doi:10.1038/s41591-021-01432-4
31. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status—New York, May 3–July 25, 2021. Morbidity and Mortality Weekly Report. 2021;70(34):1150.
32. Dimitriadis S, Meacham G, Irwin S, et al. Humoral and cellular immune responses to wild-type and omicron (B. 1.1. 529) SARS-CoV-2 variants following a fourth COVID-19 vaccination in liver transplant recipients and patients with autoimmune hepatitis. Journal of hepatology. 2022;77:S58.
33. Ribeiro AC, Laurindo IM, Guedes LK, et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis care & research. 2013;65(3):476-480.
34. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489-1501. e15.
35. Duclos H, Maillot MC, Galanaud P. Differential effects of azathioprine on T cells regulating murine B-cell function. Immunology. Jul 1982;46(3):595-601.
36. Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Annals of the rheumatic diseases. Oct 2021;80(10):1330-1338. doi:10.1136/annrheumdis-2021-220647
37. Benotmane I, Gautier-Vargas G, Cognard N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int. Jun 2021;99(6):1498-1500. doi:10.1016/j.kint.2021.04.005
38. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. May 2000;47(2-3):85-118. doi:10.1016/s0162-3109(00)00188-0
39. Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. Arthritis & rheumatology (Hoboken, NJ). Jan 2023;75(1):E1-e16. doi:10.1002/art.42372
40. Trontzas IP, Kyriakoulis KG, Vathiotis IA, et al. Vaccine-related autoimmune hepatitis: emerging association with SARS-CoV-2 vaccination or coincidence? Vaccines. 2022;10(12):2073.